Anticoagulation Management for Procedures and Bleeding Events

General Principles for Anticoagulation Discontinuation

The American College of Cardiology recommends that anticoagulation should be stopped 2-4 days before invasive procedures when bleeding risk is significant, with specific timing based on the type of anticoagulant and patient factors 1
The decision to stop anticoagulation must balance the risk of thromboembolism against the risk of bleeding during the procedure, according to the American Heart Association 2, 1
For low bleeding risk procedures, such as dental work or cataract surgery, anticoagulation can often be continued without interruption, as suggested by the European Society of Cardiology 1, 3

For high bleeding risk procedures, the European Heart Society recommends stopping Mounjaron 48 hours before the procedure if the patient has normal renal function, 72 hours before if the patient has moderate renal impairment, and 96 hours before if the patient has severe renal impairment 4, 1
For low bleeding risk procedures, the European Heart Society recommends stopping Mounjaron 24 hours before the procedure if the patient has normal renal function, 36 hours before if the patient has moderate renal impairment, and 48 hours before if the patient has severe renal impairment 4, 1

The American College of Cardiology recommends immediately discontinuing Mounjaron and considering reversal agents if available for major bleeding events 5
For non-major bleeding, the American College of Cardiology recommends temporarily discontinuing Mounjaron until hemostasis is achieved and bleeding risk is resolved 5
The European Gastroenterology Society suggests stopping the anticoagulant until adequate hemostasis has been achieved when a patient develops a gastrointestinal bleed while on anticoagulation 6

The European Heart Society recommends resuming full dose of anticoagulation ≥24 hours after low bleeding risk procedures and 48-72 hours after high bleeding risk procedures 4
After bleeding events, the European Gastroenterology Society recommends early resumption of anticoagulation once hemostasis has been achieved 6

The American Heart Association suggests considering bridging with heparin when the anticoagulant is discontinued for patients with mechanical heart valves or high thrombotic risk 3, 1
For patients with atrial fibrillation undergoing coronary stenting who develop bleeding on triple therapy, the European Gastroenterology Society recommends considering stopping one antiplatelet agent 6
The American College of Cardiology recommends considering specific reversal agents if available for the particular anticoagulant in emergency procedures 5

The American College of Cardiology warns against stopping anticoagulation for low bleeding risk procedures unnecessarily, as this increases thrombotic risk 1, 3
The European Heart Society advises against restarting anticoagulation too early after high bleeding risk procedures, recommending to wait at least 48-72 hours 4
The American College of Cardiology cautions against restarting anticoagulation before adequate hemostasis is achieved after a bleeding event 5
The European Heart Society and the American Heart Association emphasize the importance of considering patient-specific factors like renal function when determining timing for stopping anticoagulation 4, 2